Study to Evaluate the Effects of Two Doses of MBX-8025 in Subjects With Primary Biliary Cirrhosis (PBC)
Status:
Terminated
Trial end date:
2016-07-01
Target enrollment:
Participant gender:
Summary
A 12-week, double-blind, randomized, placebo-controlled, Phase 2 study, to evaluate the
effects of two doses of seladelpar/MBX-8025 in subjects with Primary Biliary Cirrhosis (PBC)
and an inadequate response to ursodeoxycholic acid (UDCA)